quinazolines has been researched along with quinacrine in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ha, SH; Shao, BR; Zhan, CQ | 1 |
| Cussac, D; Denis, C; Paris, H; Schaak, S | 1 |
| Gillespie, GY; Green, SC; Lobo, MR; Pike, MM; Schabel, MC; Woltjer, RL | 1 |
| De, S; Dermawan, JK; Dowlati, A; Gurova, K; Narla, G; Pink, J; Sharma, N; Stark, GR | 1 |
| Gillespie, GY; Lobo, MR; Pike, MM; Wang, X; Woltjer, RL | 1 |
5 other study(ies) available for quinazolines and quinacrine
| Article | Year |
|---|---|
[Evaluation of the phototoxicity of five antimalarial agents and praziquantel in mice].
Topics: Animals; Antimalarials; Chloroquine; Female; Male; Mice; Naphthyridines; Photosensitivity Disorders; Praziquantel; Quinacrine; Quinazolines; Quinolines; Ultraviolet Rays | 1986 |
alpha 2B-adrenergic receptor activates MAPK via a pathway involving arachidonic acid metabolism, matrix metalloproteinases, and epidermal growth factor receptor transactivation.
Topics: Active Transport, Cell Nucleus; Adaptor Proteins, Signal Transducing; Adaptor Proteins, Vesicular Transport; Animals; Arachidonic Acid; Bacterial Proteins; Brimonidine Tartrate; Butadienes; Cell Line; Cell Nucleus; Dose-Response Relationship, Drug; Enzyme Activation; Enzyme Inhibitors; ErbB Receptors; MAP Kinase Signaling System; Matrix Metalloproteinases; Microscopy, Fluorescence; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Models, Biological; Nitriles; Pertussis Toxin; Phosphorylation; Protein Binding; Proteins; Quinacrine; Quinazolines; Quinoxalines; Rats; Receptors, Adrenergic, alpha-2; Shc Signaling Adaptor Proteins; Src Homology 2 Domain-Containing, Transforming Protein 1; Swine; Transcriptional Activation; Tyrphostins; Virulence Factors, Bordetella | 2002 |
Quinacrine synergistically enhances the antivascular and antitumor efficacy of cediranib in intracranial mouse glioma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blotting, Western; Capillary Permeability; Drug Synergism; Female; Glioma; Magnetic Resonance Imaging; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Quinacrine; Quinazolines; Tumor Burden; Tumor Cells, Cultured | 2013 |
Quinacrine overcomes resistance to erlotinib by inhibiting FACT, NF-κB, and cell-cycle progression in non-small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; DNA; DNA-Binding Proteins; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; High Mobility Group Proteins; Humans; Luciferases; Lung Neoplasms; Mice; Mice, Nude; NF-kappa B p50 Subunit; Quinacrine; Quinazolines; RNA, Small Interfering; Transcriptional Elongation Factors; Xenograft Model Antitumor Assays | 2014 |
Combined efficacy of cediranib and quinacrine in glioma is enhanced by hypoxia and causally linked to autophagic vacuole accumulation.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Brain Neoplasms; Cell Hypoxia; Cell Line, Tumor; Enzyme Activation; Glioma; Mice; Proto-Oncogene Proteins c-akt; Quinacrine; Quinazolines; Vacuoles | 2014 |